Titre :

Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults

Auteur(s) :

Serris, Alexandra [Auteur]
Université Paris-Est Créteil Val-de-Marne - Paris 12 [UPEC UP12]
Amoura, Zahir [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Canoui-Poitrine, Florence [Auteur]
Université Paris-Est Créteil Val-de-Marne - Paris 12 [UPEC UP12]
Terrier, Benjamin [Auteur]
Université Paris Descartes - Paris 5 [UPD5]
Hachulla, Eric [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Costedoat-Chalumeau, Nathalie [Auteur]
Université Paris Descartes - Paris 5 [UPD5]
Papo, Thomas [Auteur]
Lambotte, Olivier [Auteur]
Saadoun, David [Auteur]
Hie, Miguel [Auteur]
Blanche, Philippe [Auteur]
Université Paris Descartes - Paris 5 [UPD5]
Lioger, Bertrand [Auteur]
Gottenberg, Jacques-Eric [Auteur]
Godeau, Bertrand [Auteur]
Université Paris-Est Créteil Val-de-Marne - Paris 12 [UPEC UP12]
Michel, Marc [Auteur]
Université Paris-Est Créteil Val-de-Marne - Paris 12 [UPEC UP12]

Titre de la revue :

American Journal of Hematology

Nom court de la revue :

Am. J. Hematol.

Numéro :

93

Pagination :

424-429

Date de publication :

2018-03

ISSN :

0361-8609

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

The aim of the study was to assess the efficacy and safety of rituximab (RTX) for treating systemic lupus erythematosus (SLE)-associated immune cytopenias. This multicenter retrospective cohort study of adults from ...
Lire la suite >The aim of the study was to assess the efficacy and safety of rituximab (RTX) for treating systemic lupus erythematosus (SLE)-associated immune cytopenias. This multicenter retrospective cohort study of adults from French referral centers and networks for adult immune cytopenias and SLE involved patients >/=18 years old with a definite diagnosis of SLE treated with RTX specifically for SLE-associated immune cytopenia from 2005 to 2015. Response assessment was based on standard definitions. In total, 71 patients, 61 women (85.9%), with median age 36 years [interquartile range 31-48], were included. The median duration of SLE at the time of the first RTX administration was 6.1 years [2.6-11.6] and the reason for using RTX was immune thrombocytopenia (ITP) for 44 patients (62.0%), autoimmune hemolytic anemia (AIHA) for 16 (22.5%), Evans syndrome for 10 (14.1%), and pure red cell aplasia for one patient. Before receiving RTX, patients had received a mean of 3.1 +/- 1.3 treatments that included corticosteroids (100%), and hydroxychloroquine (88.5%). The overall initial response rate to RTX was 86% (91% with ITP, 87.5% with AIHA, and 60% with Evans syndrome), including 60.5% with complete response. Median follow-up after the first injection of RTX was 26.4 months [14.3-71.2]. Among 61 initial responders, relapse occurred in 24 (39.3%); for 18, RTX retreatment was successful in 16 (88.8%). Severe infections occurred after RTX in three patients, with no fatal outcome. No cases of RTX-induced neutropenia were observed. In conclusion, RTX seems effective and relatively safe for treating SLE-associated immune cytopenias.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Inserm
Université de Lille
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Équipe(s) de recherche :

Immunity, inflammation and fibrsis in auto and allo-reactivity

Date de dépôt :

2019-03-01T14:09:26Z
2024-01-25T14:12:39Z